New treatments compared to established treatments in randomized trials (Q24245989)

object named as

GE Vist

0 references

author name string

HP Soares

0 references

A Kumar

0 references

M Johansen

0 references

E Paulsen

0 references

I Chalmers

0 references

B Djulbegovic

Cochrane Database of Systematic Reviews

0 references

publication date

19 July 2006

0 references

published in

0 references

cites work

The scandal of poor medical research

1 reference

https://api.crossref.org/works/10.1002%2F14651858.MR000024

Statistics notes: Absence of evidence is not evidence of absence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.MR000024

What is the prior probability of a proposed new treatment being superior to established treatments?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.MR000024

The importance of preservation of the ethical principle of equipoise in the design of clinical trials: relative impact of the methodological quality domains on the treatment effect in randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.MR000024

Trials: the next 50 years. Large scale randomised evidence of moderate benefits

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.MR000024

Subverting randomization in controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.MR000024

7 January 2021

The hazards of scoring the quality of clinical trials for meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.MR000024

7 January 2021

Factors associated with failure to publish large randomized trials presented at an oncology meeting

1 reference

https://api.crossref.org/works/10.1002%2F14651858.MR000024

7 January 2021

Evaluation of new treatments in radiation oncology: are they better than standard treatments?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.MR000024

7 January 2021

How study design affects outcomes in comparisons of therapy. I: Medical

1 reference

https://api.crossref.org/works/10.1002%2F14651858.MR000024

7 January 2021

Acknowledgment of uncertainty: a fundamental means to ensure scientific and ethical validity in clinical research

1 reference

https://api.crossref.org/works/10.1002%2F14651858.MR000024

7 January 2021

Why register clinical trials?--Revisited

1 reference

https://api.crossref.org/works/10.1002%2F14651858.MR000024

7 January 2021

The uncertainty principle and industry-sponsored research

1 reference

https://api.crossref.org/works/10.1002%2F14651858.MR000024

7 January 2021

Cochrane review on screening for breast cancer with mammography.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.MR000024

7 January 2021

Industry-sponsored research

1 reference

https://api.crossref.org/works/10.1002%2F14651858.MR000024

7 January 2021

Thirty years of Medical Research Council randomized trials in solid tumours

1 reference

https://api.crossref.org/works/10.1002%2F14651858.MR000024

7 January 2021

Equipoise and the ethics of clinical research

1 reference

https://api.crossref.org/works/10.1002%2F14651858.MR000024

7 January 2021

Bias in clinical intervention research.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.MR000024

7 January 2021

Medical ethics and controlled trials.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.MR000024

7 January 2021

Pharmaceutical industry sponsorship and research outcome and quality: systematic review

1 reference

https://api.crossref.org/works/10.1002%2F14651858.MR000024

7 January 2021

Bad reporting does not mean bad methods for randomised trials: observational study of randomised controlled trials performed by the Radiation Therapy Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.MR000024

7 January 2021